TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03522454

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-rich oral nutritional supplement
Description: Ready-to-drink beverage containing 20 g protein and 1.5 g hydroxymethylbutyrate (HMB) per serving, consumed twice daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based supervised exercise program
Description: WEBB (Weight-bearing Exercise for Better Balance) program combining walking and weight-bearing exercises to build strength and balance, administered by a trained therapist at the participant's home.
Study: NCT03908671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized mRNA Tumor Vaccine
Description: subcutaneous injection with personalized mRNA tumor vaccine
Study: NCT04477330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: 1 mA tDCS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle motor training
Description: Visuomotor target tracking task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval speed based treadmill training (HIISTT)
Description: Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down.
Study: NCT01338987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Second choice is Busulfan (with goal steady state of 800-1000) with fludarabine or cyclophosphamide at myeloablative dosing or non-myeloablative dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given with Busulfan as alternative to cyclophosphamide in second transplant setting only
Study: NCT04477330

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: High intensity interval speed based treadmill training (HIISTT)
Description: Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down.
Study: NCT02838199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3
Study: NCT01338987

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second Allogeneic Bone Marrow Transplantation
Description: Second Allogeneic Bone Marrow Transplantation
Study: NCT04445779

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before surgical procedure.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coenzyme Q10
Description: Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before surgical procedure.
Study: NCT00003034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranpirnase
Description: Given IV
Study: NCT02420418

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl-cysteine (NAC)
Description: Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in outpatient smokiing cessation. The dosage will be fixed 1800 mg/day of NAC administered in capsules taken 2 before breakfast and 2 before dinner is equal doses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in smoking cessation service
Study: NCT01144364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [Mabthera/Rituxan]
Description: Intravenous repeating dose
Study: NCT02071953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental adhesive w/out phosphoric acid in post. rest.
Description: Experimental adhesive without phosphoric acid in posterior restorations

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental adhesive with phosphoric acid in post. rest.
Description: Experimental adhesive with phosphoric acid in posterior restorations
Study: NCT02405949

Intervention type: GENETIC
Intervention: Genetic test
Description: Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .

Intervention type: GENETIC
Intervention: Genetic test
Description: Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .

Intervention type: GENETIC
Intervention: Genetic test
Description: Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .

Intervention type: GENETIC
Intervention: Genetic test
Description: Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .
Study: NCT00350649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard CBT
Description: Manualized delivery of CBT by trained clinicians

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT+CM/adherence
Description: CBT and Clinical Management for attendance and completing homework

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM/abstinence
Description: Contingency Management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CM/abstinence+CBT
Description: Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician
Study: NCT02451098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin10mg, Ezetimibe10mg
Description: Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin10mg, Ezetimibe placebo
Description: Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin20mg, Ezetimibe10mg
Description: Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin20mg, Ezetimibe placebo
Description: Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin40mg, Ezetimibe10mg
Description: Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin40mg, Ezetimibe placebo
Description: Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)
Study: NCT03166553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elemene
Study: NCT01601366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Description: The study includes 2 treatment groups: Group I the LNG-IUS group where they will have a LNG IUS inserted for them

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined oral contraceptives
Description: Group II: will recite combined oral contraceptives for 6 months
Study: NCT01970865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days

Intervention type: DRUG
Group type: OTHER
Intervention: Crizotinib
Description: Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
Study: NCT04111848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will be assigned into 2 groups (each of 45):~Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine and magnesium
Description: Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
Study: NCT00231257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
Description: Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Brachytherapy
Study: NCT03263039

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg Q3W
Study: NCT03218163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 Maintenance
Description: Cycle 1 - Days 1, 8, 15, and 22: 4mg/kg IV Cycles 2-12 - Day 1: 4mg/kg IV
Study: NCT01699386

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Study Formula
Description: feed as lib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Study Formula
Description: feed as lib
Study: NCT01458106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB031 (rFVIIIFc)
Description: Vials of rFVIIIFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FVIII (PK subgroup only)
Description: Baseline prestudy FVIII dosing in participants who enter the PK subgroup. Vials of prestudy FVIII were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
Study: NCT05541991

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: single dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract
Description: coated tablet with a single dose of standardised rhubarb extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo coated tablet
Description: coated tablet without active principle

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: double dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract
Description: coated tablet with a double dose of standardised rhubarb extract
Study: NCT03805308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-arterial Therapy
Description: Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels.
Study: NCT02441244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visbiome
Description: Visbiome probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02526511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeling Magnetic Resonance Imaging
Description: Undergo arterial spin labeled perfusion magnetic resonance imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo dynamic contrast-enhanced perfusion magnetic resonance imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion Magnetic Resonance Imaging
Description: Undergo perfusion magnetic resonance imaging
Study: NCT03095118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Intravenously (IV) at a dose of 16 mg/kg once weekly for 8 weeks, followed by once every 2 weeks for eight additional doses
Study: NCT03023514

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Lipoic acid
Description: 300 mg ALA x2 (1pill orally/12h) to the recipient from the day of the donors pick up until 8 week of pregnancy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Progesterone
Description: 200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Progesterone
Description: 200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
Study: NCT01244061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 1mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo twice daily
Study: NCT02442583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brochure regarding sedentary behavior
Description: This pilot will occur in two phases. Phase 1 will occur in two steps. In Step 1, we will conduct one-on-one telephone interviews with 15 early stage CRC (colorectal cancer) survivors to obtain their knowledge and insights about sedentary behaviors and ways to reduce them. Their input will be used to help create a brochure on sedentary behaviors. In Step 2, we will conduct one-on-one telephone interviews with 5 early stage CRC survivors to provide feedback about the brochure. In Phase 2, we will recruit 15 CRC survivors. After completing a baseline survey, they will be asked to both wear an ActiGraph and self-report their daily sedentary behaviors for one week. They will receive tailored feedback as to their average weakly levels of sedentary behaviors and receive the brochure. One month post-intervention, they will be asked to take part in telephone survey assessing sedentary behaviors, PA (physical activity), and use of brochure.
Study: NCT03992417

Intervention type: DRUG
Intervention: Dupilumab SAR231893 (REGN668)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection
Study: NCT03736629

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03833622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Aid Assessment
Description: Provide feedback on a shared decision making tool to aid in discussion on goals of care in the emergency department
Study: NCT03624764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparostopic promontofixation using surgical glue
Description: The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by the surgical glue (cyanoacrylate biocompatible adhesive)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparostopic promontofixation using threads
Description: The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by sutures with threads
Study: NCT02616185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06755992
Description: PF-06755992 will be administered on Day 1 of Cycles 1 and 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06755990
Description: PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDS-IM Electroporation Device
Description: TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: PF-06753388 will be administered every 28 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: PF-06801591 will be administered every 28 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06753512
Description: Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab
Study: NCT03617029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcoil
Description: Needle localization with microcoil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipiodol
Description: Needle localization with contrast injection
Study: NCT02838199

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SAVR
Study: NCT00089271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvespimycin hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01541527

Intervention type: BIOLOGICAL
Intervention: blood test
Description: One blood test entering in the usual follow-up of the patient
Study: NCT02299713

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.
Study: NCT03405493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wake and Light Therapy
Description: Participants will be helped to change the pattern sleep by depriving participants of sleep for one night. On Day 1 participants will be supported to stay up all night and the following day at the Hospital. Participants can go to bed by 5pm at home on Day 2. Participants will need to get up by about 1am and return to the hospital to be supported to stay awake. Participants will then go to bed at 7pm on Day 3. Participants will be asked to sleep until 3am and then stay awake at home until bed at 9pm on Day 4. Participants will then get up by 5am on Day 5 and stay awake until 11pm to resume a normal sleep routine waking by 7am on Day 6. Participants will also be given a light box to use each morning. For the light box, participants will be asked to sit about one foot away from a light box. You will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes. Participants may continue to have treatment as usual.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and Light Therapy
Description: Participants will be given information and advice on how to get a good night's sleep. Participants will be also given a light box to use in the morning for 1 week. For the light box, participants will be asked to sit about one foot away from a light box. Participants will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes when you get up. Participants may continue to have any treatment as usual (for example medication or talking therapies).
Study: NCT00700531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLC removal HD (Gambro HCO 1100)
Description: FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dialysis on a high flux ployflux dialyser
Description: Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
Study: NCT04392206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose Derived Mesenchymal Stem Cells
Description: The dose will be specifically tailored to each subject's vascular anatomy determined by the surgeon through ultrasound measurements. Approximately 3-5 million cells in 5ml Ringer Lactate (RL) Solution